affiliation not provided to SSRN
Optimal Rule-Based General A+B Design in Phase I Clinical Trials
Dose-limiting toxicity (DLT), general A+B, interactive R Shiny, maximum tolerated dose (MTD), target toxicity level, traditional "3+3"